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The emerging role of the microbiome in human health and dis-
ease is being defined across various diseases and disorders that 
span every aspect of human illness. Diseases, their progres-
sion, and even human behaviors not imagined to be influenced 
by our microbiome are now being defined by subtle changes in 
the composition and function of microbiota present in various 
compartments from skin to feces. There is no doubt that nutri-
tion, from as early as in utero, through the neonatal period, and 
up to adulthood, has a profound effect on the shape and trajec-
tory of our body’s microbiome. Technical capabilities in 
genomics, proteomics and metabolomics, and bioinformatic 
management are now a reality, and the information generated 
is nothing short of startling in revealing the immense influence 
that our microbiome has on our early development, behaviors, 
susceptibility to disease, and recovery from disease. Although 
the data display can be enormous and appear complicated at 
first, advances in bioinformatics and biostatistics are making 
pattern and signature recognition ever more understandable 
even to the uninitiated. Interpretation of changes in the compo-
sition and function of the microbiome must also be contextual-
ized to the spatial and temporal dynamics that constantly exist 
in complex microenvironments such as the mouth, gut, vagina, 
skinfolds, and elsewhere. The virtually limitless capacity to 
sample and analyze across the spatioregional landscape of 
these various compartments and provide temporal and clinical 
contexts to the development of and recovery from disease has 
the potential to generate an unimaginable number of novel 
hypotheses to explain conditions that have remained beyond 
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Abstract
The human and earth microbiomes are among the most important biological agents in understanding and preventing disease. Technology 
is advancing at a fast pace and allowing for high-resolution analysis of the composition and function of our microbial partners across 
regions, space, and time. Bioinformaticists and biostatisticians are developing ever more elegant displays to understand the generated 
megadatasets. A virtual cyberinfrastructure of search engines to cross-reference the rapidly developing data is emerging in line with 
technologic advances. Nutrition science will reap the benefits of this new field, and its role in preserving the earth and the humans who 
inhabit it will become evidently clear. In this report we highlight some of the topics of an A.S.P.E.N.-sponsored symposium held during 
Clinical Nutrition Week in 2013 that address the importance of the human microbiome to human health and disease. (JPEN J Parenter 
Enteral Nutr. 2014;38:167-178)
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the reach of medical science, such as autism, antibiotic resis-
tance, outcome from sepsis, and autoimmune disease, to name 
a few. Sequence technology and mass spectroscopy are becom-
ing better, faster, and cheaper. The future of medical science 
will embrace these efforts as systems biology takes the front 
stage in explaining the human condition, from early develop-
ment to disease incidence and disease recovery.
Nutrition science will reap enormous benefits in defining 
the systems biology of human disease since what and how we 
eat affects every aspect of our integrated physiology. The “first 
pass” aspect of nutrients as they enter the human intestinal bio-
reactor is an open line of inquiry. When this first pass effect is 
eliminated, such as occurs with parenteral nutrition, much of 
human physiology is changed. When antibiotics alter the 
human intestinal bioreactor, nutrients, drugs, and overall 
metabolism are changed. Finally, when foreign invaders take 
hold, such as occurs in Clostridium difficile colitis, reestablish-
ing the core microbiome may be the patient’s only chance for 
recovery. Last, the etiopathogenesis of complex autoimmune 
diseases such as inflammatory bowel disease may only be dis-
entangled by understanding and defining how the microbiome 
interacts with the immune system to trigger and sustain muco-
sal inflammation.
In this report, leaders in the field of microbiome research 
highlight a few of the above concepts. The symposium took 
place as a workshop during Clinical Nutrition Week in February 
2013. The workshop was organized to introduce the idea that 
nutrients play a major role in shaping a core microbiome that 
directly interacts with every aspect of human physiology, 
immune function, and health. As such, nutrition science and its 
clinical application will need to align with efforts in microbi-
ome research and incorporate many of its finding into research 
and clinical care in the field.
A major aspect of incorporating microbiome research into 
nutrition sciences is to recognize the importance of diversity as 
a key determinant of microbial community health and func-
tion. This is reviewed by Dr. Jack Gilbert, associate professor 
of ecology and evolution. Recognizing the effect of nutrition 
management on the microbiome is also important, and this is 
addressed by Dr. Daniel H. Teitelbaum, professor of pediatric 
surgery. Precisely how the microbiome influences the inci-
dence and progression of complex diseases such as necrotizing 
enterocolitis and inflammatory bowel disease is addressed 
by Dr. Michael J. Morowitz, assistant professor of pediatric 
surgery and Dr. B. Eugene Chang, professor of medicine. Last, 
Dr. Michael J. Sadowsky, professor of microbiology, and oth-
ers discuss how disease states such as recalcitrant and relaps-
ing C difficile diarrhea may progress beyond antibiotics and 
nutrition management and may require refaunation of the core 
microbiome through fecal transplantation.
Closing remarks by Dr. John Alverdy, professor of surgery 
and director of the workshop, explain how the incidence 
and outcome of sepsis may be influenced by loss of the core 
microbiome and how future strategies might include methods 
to preserve the core microbiome.
What is learned is that microbial communities are diverse, 
complex, and important components of the biology of all 
higher animals, including humans. Research is just beginning 
to elucidate these complexities and is both exciting and 
daunting. As our understanding expands, it is becoming 
clear that all facets of medical science will need to incorpo-
rate microbiome effects into current paradigms of disease 
pathophysiology.
Modeling the Microbiome: Creating 
Predictive Models From Deterministic 
Patterns (Jack Gilbert)
Most microbial communities exhibit exquisitely complex 
structure. Many aspects of this complexity, from the number of 
species to the total number of interactions, are currently very 
difficult to examine directly. However, extraordinary efforts 
are being made to make these systems accessible to scientific 
investigation. While recent advances in high-throughput 
sequencing technologies have improved accessibility to the 
taxonomic and functional diversity of complex communities, 
monitoring the dynamics of these systems over time and 
space—using appropriate experimental design—is still expen-
sive and not commonplace. Fortunately, modeling can be used 
as a lens to focus low-resolution observations of microbial 
communities to enable mathematical abstractions of functional 
and taxonomic dynamics. Here we review the approaches for 
modeling bacterial diversity at both the very large and the very 
small scales at which microbial systems interact with their 
environments.
To understand microbial systems, it is necessary to consider 
the scales at which they interact with their environment. These 
scales range spatially from microns to kilometers and tempo-
rally from eons to hours. Accounting for 350–550 billion tons 
of extant biomass, microbes are the principal form of life on 
earth, and they have dominated earth’s evolutionary history.1 
While their effects might be global, microbial systems interact 
with their environments at microscopic scales. A single gram 
of soil might contain around 109 microbial units,2 and an aver-
age milliliter of seawater will contain approximately a million 
bacterial cells. The wide taxonomic diversity of the popula-
tions3 is fostered, at least in part, by myriad micro-environ-
ments accessible to the bacteria. In soil and marine systems, 
the majority of microbial diversity is represented in the minor-
ity of biomass.3–6 Generally, in highly diverse microbial com-
munities a few highly abundant taxa predominate in a 
community with a long tail of low abundance taxa.4 These low-
abundance taxa in particular are crucial to our understanding of 
microbial ecosystems, as they represent the vast functional 
diversity that can rapidly blossom to high abundance under the 
appropriate environmental conditions.7,8
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Microbial systems can be described using environmental 
DNA sequence information and contextual metadata, which 
reveal dynamic taxonomic and functional diversity across gra-
dients of natural or experimental variation.9–13 Taxonomic 
diversity is a measure of the community species composition 
and relative abundance of its members, which is maintained or 
altered via interactions and adaptations between each species 
and with environment. Functional diversity is a measure of the 
frequency and the type of predicted enzyme functions encoded 
in a community’s metagenome and represents the potential to 
express a phenotype that interacts with a particular environ-
mental state. The continuously increasing depth of observation 
provided by contemporary sequencing technologies has now 
enabled whole genomes to be reassembled from metagenomic 
data, which permits appropriate descriptions of the taxonomic 
and functional potential of individual species imbedded within 
each community.14–16
Each community, whether on the epithelial lining of the gut, 
in an oral cavity, embedded in a desiccated soil particle, or in a 
biofilm attached to a hermit crab in a coral sea, presents a poten-
tially unique set of interactions with the ecosystem. Microbial 
ecology aims to characterize these dynamics in different envi-
ronments and identify trends and relationships that predict these 
dynamic patterns. The aim is to generate predictive models that 
incorporate taxonomic and functional diversity into the biologi-
cal, chemical, and physical interactome, for microbial communi-
ties at the micro (bottom-up) and macro (top-down) scales.
The human microbiome is particularly interesting as it 
shows both amazing resilience to perturbation and also 
dynamic variability over time and body site.17 The stability of 
the microbiome in humans has been shown to increase with the 
age of the subject. In fact, during the first year of life microbial 
communities are extremely unstable, and they start to reach 
“adult” stability around 1–1.5 years of age.18 Their diversity 
and stability have been linked to many aspects of human dis-
ease, including mental health and neurological conditions in 
general.19,20 Of specific interest is the role that the intestinal 
microbiota plays in neurological conditions such as autism,21-25 
with strong evidence that the microbiome shows significant 
correlations with autistic traits.26 To determine where the 
microbes that colonize our bodies and affect our health and 
well-being originate, we have instigated a series of compre-
hensive studies into the microbiology of homes (www.home-
microbiome.com) and hospitals (www.hospitalmicrobiome.
com). These are designed with longitudinal interpretation in 
mind, so that the diversity and succession of the bacteria in 
these living environments can be tracked against the resultant 
microbial colonization and shed from the humans and animals 
in that ecosystem. The aim is to create predictive models that 
can be used to predict when certain types of bacteria will 
become abundant and what that will mean in terms of impacts 
on human and building health. Comprehensively, this means 
encapsulating the relationships between bacteria, the environ-
ments, and the humans and animals that live in those 
ecosystems. This will lead to the development new architec-
tural and building design practices.
Parenteral Nutrition and the Intestinal 
Microbiome (Daniel H. Teitelbaum)
Parenteral nutrition (PN), or enteral nutrient deprivation, is com-
monly used as treatment for many patients, ranging from short-
term use in patients with gastrointestinal dysfunction27 to 
long-term use in patients with short bowel syndrome.28 While it 
is life-saving for many, PN use is associated with numerous 
complications ranging from an increase in enteric-derived infec-
tions to a loss of immune reactivity.29,30 Previous studies from 
our laboratory and others have shown that in a mouse model of 
PN, a number of significant physical and immunologic changes 
occur in the intestinal mucosa.31 Physically, there is atrophy of 
small intestinal villi, an increase in intestinal epithelial cell apop-
tosis, and a decrease in intestinal epithelial cell proliferation.32 
Immunologically, a proinflammatory state develops within the 
gastrointestinal tract, including increased mucosal and intraepi-
thelial lymphocyte-derived tumor necrosis factor-α (TNF-α), 
interferon-γ, and decreased interleukin-10.33,34 However, the 
mechanisms driving these changes are unknown. The implica-
tions of this shift toward a proinflammatory state, however, can 
be a major contributor to the known association of PN with sub-
sequent loss of epithelial barrier function34–36 and increases in 
bacterial translocation.37,38
Over the past few years, the scientific community has 
developed a great appreciation for the dependence of the intra-
luminal microbial population on the supply of enteral nutrients 
delivered to these microbes. The intestinal microbiota is highly 
sensitive to local environmental changes, and the composition 
of the population may be rapidly altered in response to such 
dramatic changes in the local environment.39,40 Because of this, 
our group hypothesized that the acute deprivation of enteral 
nutrition with the administration of PN would place the intesti-
nal microbiota into an abrupt state of nutrient withdrawal. The 
consequences of PN administration on the resident microbial 
community during this environmental change have not been 
fully addressed but might have far-reaching consequences on 
the health of the host.
Figure 1 shows a dramatic shift in the composition of the 
microbial population with the administration of PN from 
Firmicutes-rich to a population dominated by Proteobacteria 
and Bacteroides.41 The major way that these microbes signal 
host enterocytes and immunocytes is via the Toll-like receptor 
pathway and through the myeloid differentiation primary 
response gene 88 (MyD88), with subsequent activation of 
nuclear factor-κ (NFκB) signaling. NFκB activation is known to 
mediate the expression of several proinflammatory cytokines 
including TNF-α.42 We have demonstrated that blockade of the 
MyD88 pathway using MyD88 knockout mice resulted in pre-
vention of the proinflammatory state within the epithelium of 
the small bowel, with subsequent preservation of T-regulatory 
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cells and maintenance of epithelial barrier function. This sug-
gests that the shift toward a Proteobacteria-rich intraluminal 
environment may be a key trigger for many of the adverse events 
seen with PN administration. Future work will examine whether 
prevention of these microbial shifts can also prevent the 
PN-related proinflammatory state. Another fascinating area is 
the marked expansion in the Verruco microbial population with 
PN and a further expansion in this population in MyD88 KO 
mice (Figure 1). This group of organisms, particularly the domi-
nant species Akkermansia muciniphila, thrives on mucous and 
has been associated with a number of pathologic processes, 
including obesity.43 It also intriguing that administration of PN is 
associated with a marked increase in intestinal goblet cells and 
altered mucous production,44 suggesting that these microbes 
may be expanding to take advantage of a new nutrient source—
the patient’s own mucous.
Whether such changes in the intestinal microbial population 
occur in humans receiving PN has only recently been exam-
ined. Our laboratory had the opportunity to examine a series of 
human small bowel specimens harvested at the time of surgery 
Figure 1. Summary of 454 pyrosequencing results from mucosally derived microbial populations in enterally fed and enterally 
deprived (parenteral nutrition) populations of mice. Note a dramatic shift in the composition of the microbial population with the 
administration of PN, from Firmicutes-rich to a population dominated by Proteobacteria and Bacteroides. Note also an expansion of 
the Verrucomicrobia population in MyD88 (a common signaling protein for the immune signaling of bacterial products) knockout mice. 
Results are derived from Miyasaka et al.41
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from patients who had segments of bowel that lacked exposure 
to enteral nutrition for a prolonged period of time (>2 weeks). 
Interestingly, 454 pyrosequencing of these specimens demon-
strated a shift in the microbial population between segments 
that were or were not exposed to enteral nutrients45 (Figure 2). 
While the significance of these microbial population shifts has 
not been fully examined, they suggest that patients receiving 
PN may undergo changes similar to those seen in mice.
Thus, nutrient deprivation appears to have profound 
changes in the microbial populations of both mouse models 
and humans. Future challenges will include our ability either to 
block virulent pathogens in the gut lumen from effectively sig-
naling a patient’s immunocytes and forming a proinflamma-
tory state or to provide a healthier luminal environment, during 
PN administration, that will sustain a more favorable microbial 
population.
Host-Microbe Interactions in Babies 
at Risk for Necrotizing Enterocolitis 
(Michael J. Morowitz)
Necrotizing enterocolitis (NEC), a disease characterized by 
severe intestinal inflammation that can progress to multiorgan 
failure and death, remains an important source of morbidity 
and mortality among premature infants.46 The disease provides 
one of the starkest examples of the intersection between nutri-
tion and human pathology, since epidemiologic studies have 
consistently shown the incidence of the disease to be signifi-
cantly higher in babies receiving artificial formula than babies 
receiving maternal milk.47 Although it has long been suspected 
that abnormal patterns of gut bacterial colonization contribute 
to NEC pathogenesis,39,47 we lack an understanding of specific 
mechanisms by which bacteria might trigger the excessive gut 
inflammation and epithelial cell death seen in the disease. 
However, recent advances in high-throughput platforms have 
made it possible to revisit the relationship between babies and 
gut microbes at high resolution.
The complex interactions between the gut epithelium and 
intestinal microbes can be mutually beneficial; for example, 
bacteria can serve specific functions such as vitamin produc-
tion and in return they benefit from the nutrient-rich microen-
vironment of the human gut.48 Current understanding of such 
symbioses in the human gut is relatively limited, but there is 
much to be learned from studies of the host-microbe relation-
ship in well-studied model organisms such as the Hawaiian 
Bobtail Squid. Within hours after newborn squid have hatched, 
a mucus layer within specialized epithelial cells of the squid 
light organ becomes colonized by a Vibrio species of marine 
bacteria with luminescent properties. This specific bacterial 
population ultimately contributes to the health and fitness of 
the squid throughout its lifespan.49 Elegant work in this field 
has demonstrated how the squid and the bacteria “find each 
other” using a molecular dialogue. Remarkably, despite the 
high microbial diversity in ocean waters, it seems that only 
Vibrio fischeri is capable of successfully colonizing the squid 
light organ.
Lessons learned from model symbiotic relationships such 
as this have generated interest in the exploration of similarly 
sophisticated relationships established and maintained over 
time in humans. Recent research, for example, has demon-
strated how colonic bacteria can affect brain development in 
the newborn period and also coordinate the education of regu-
latory T cells.51,52 Importantly, there is increasing recognition 
that complex intestinal disorders such as NEC and inflamma-
tory bowel disease probably represent a global disruption of 
such host-microbe interactions.52,53 This is a paradigm shift 
from earlier approaches to “pathogen hunting,” in which clini-
cians and researchers have sought to find individual causative 
pathogens that could be “blamed” for microbe-related clinical 
problems. In the case of NEC, prior attempts to identify caus-
ative pathogens have been inconclusive39; babies with NEC 
have repeatedly been found to have a microbiota distinct from 
that of healthy controls, but the observed changes have varied 
across studies. In other words, it has not been possible to sat-
isfy Koch’s postulates regarding bacteria, causality, and NEC 
pathogenesis.
Advances in high-throughput platforms such as next-genera-
tion DNA sequencing have made it possible to characterize the 
dynamic process of early gut bacteria colonization in newborn 
infants at higher resolution. The utility of studying time series of 
samples rather than a limited number of samples per infant has 
been illustrated by landmark papers in the field demonstrating 
the temporal instability, low diversity, and high interindividual 
variability of gut bacterial communities in newborn infants.54,55 
Figure 2. Summary of 454 pyrosequencing results from human 
distal small bowel specimens from patient specimens where 
enteral nutrients were delivered or deprived for at least 2 weeks. 
Note a shift in microbial species with differences in degree of 
nutrient deprivation. Data derived from Ralls et al.45
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It appears that these features of gut microbial communities are 
even more pronounced in premature infants.56,57 A unique fea-
ture of gut bacterial colonization of newborn premature infants 
is that it almost always occurs in the context of the administra-
tion of broad-spectrum antibiotics. This exposure to antibiotics 
could theoretically derail normal “programs” of bacterial coloni-
zation, and in fact 2 important retrospective studies have linked 
early antibiotic exposure to an increased incidence of NEC.58,59
As noted, molecular studies of the intestinal microbiota in 
premature newborns have not identified reproducible differ-
ences between babies with and without NEC. It is becoming 
increasingly likely that taxonomic identifications alone using 
marker genes will be inadequate to resolve the pathogenesis of 
the disease. Whole genome sequencing of entire bacterial com-
munities (commonly referred to as metagenomic sequencing) 
offers the possibility to more fully understand the metabolic 
potential of mixed bacterial population and the genetic differ-
ences between closely related but nonidentical strains of bacte-
ria. Metagenomics, however, does not offer functional data 
about which metabolic and virulence pathways are activated at 
a specific time and place. For this reason, there is intense inter-
est in novel “omics” platforms that can provide functional 
information about the gut microbiota. An ideal approach might 
be to pair this functional information in real-time with tests that 
assess the health of the gastrointestinal tract.
Metaproteomics is a developing field that allows for the 
recovery and characterization of proteins directly from bio-
logic samples containing mixed populations of microbial spe-
cies. This approach stands in contrast to older proteomics 
technologies developed for individual microbial isolates grown 
in culture. A common tandem metaproteomics strategy uses 
liquid chromatography to separate complex mixtures of pro-
teins and then mass spectrometry to characterize and identify 
the proteins.60 Whereas older attempts to characterize protein 
expression in mixed microbial communities were limited by 
technical considerations, recent advances have made it possi-
ble to obtain relatively deep shotgun datasets of expressed pro-
teins. This approach has been used successfully with human 
fecal samples to determine precisely which bacterial proteins 
are expressed within the distal human gut.61,62 Such an approach 
allows for identification of actively expressed bacterial pro-
teins while simultaneously profiling human proteins that have 
been secreted into the gut lumen and/or expressed on exfoli-
ated epithelial cells. Importantly, many proteins found in high 
abundance in human stool samples—for example, mucin 2—
are known to participate in the host-microbe dialogue.63,64 
Monitoring fecal concentrations of microbial and human pro-
teins may prove useful in improving our ability to diagnose and 
treat gastrointestinal disorders such as NEC.
The increased risk of NEC in formula-fed babies could 
result from the growth of particularly virulent strains of gut 
bacteria or alternatively from the induction of virulence genes 
and proteins due to the specific nutrition components present 
in artificial formula. Efforts to untangle these considerations, 
and to decipher the contributions of gut microbes to NEC 
pathogenesis, have been reinvigorated in recent years by the 
development of high-throughput culture-independent experi-
mental platforms. At present, we still have a limited under-
standing of genomic and functional differences in the gut 
microbial communities of babies with and without NEC. 
However, in coming years, it should be possible to more clearly 
define these differences and to place microbiome data squarely 
in the context of clinical information about intestinal health. 
Ideally, an enhanced understanding of the disturbed host-
microbe relationship in NEC will be translated into improved 
diagnostics for early detection of disease and/or therapeutics to 
“rescue” unstable gut microbial communities. Outcomes for 
babies with NEC have not changed significantly over the past 
few decades, but this may soon change as we learn more about 
the host-microbe relationship during the newborn period.
The Intestinal Microbiome and 
Inflammatory Bowel Diseases (Eugene B. 
Chang)
Inflammatory bowel diseases (IBDs), as well as other immune-
related human disorders, are “Western” disorders that have sig-
nificantly increased in incidence and prevalence over the last 
half century, particularly in highly developed urban popula-
tions.65,66 While it is very clear that these diseases have a 
genetic basis, their emergence over such a short period of evo-
lutionary time is not likely caused by genetic drift67 but rather 
by exposure to nongenetic factors introduced through changes 
in the environment and lifestyle of genetically susceptible indi-
viduals, triggering aberrant host responses that lead to IBD. 
The nature of these triggering factors remains unclear, although 
important leads have been established through experimental 
models and human genome-wide studies that have increased 
our understanding of etiopathogenesis. For instance, expres-
sion qualitative trait loci and genes associated with risk poly-
morphisms implicate gut microbiota in the pathogenesis of 
IBD—that is, IBD caused by an unfortunate combination of 
aberrant gut microbiota (dysbiosis) against a background of 
genetic susceptibility. However, to explain the recent epide-
miological trends in IBD, the supposition must be made that 
the collective human microbiome of Western populations has 
shifted as a result of societal and cultural changes. In support 
of this, several studies have convincingly shown substantial 
differences in the gut microbiota of individuals from develop-
ing populations and those from Western populations. Children 
from Burkina Faso, for instance, have a substantially different 
gut microbial profile that their counterparts in the European 
Union.67 Difference in diet appeared to be the strongest corre-
lation with these findings, dominating over other possible vari-
ables such as ethnicity, sanitation, hygiene, geography, and 
climate, in shaping the gut microbiota.
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In this regard, diet is thought to play an important role in the 
increase of complex autoimmune and inflammatory disorders in 
Western countries.68 In our study, we examined whether certain 
dietary fats that are well represented in Western diets are capable 
of either precipitating or preventing/ameliorating colonic inflam-
mation through their actions on the enteric microbiome.69 On 
a background of genetic susceptibility, we hypothesized that 
these microbial changes affect host immune homeostasis, shift-
ing the state to one favoring increased risk for disease. The 
effects of the 3 different high-fat, “Western-type” diets on the 
enteric microbiota of specific pathogen-free wild-type C57Bl/6 
mice were tested. With the exception of the low-fat purified 
mouse diet, the high-fat diets were isocaloric and differed only 
in the type of dietary fat used, which was held constant at 37% 
of total calories and closely paralleled Western consumption.70 
As an aside, these fat sources are commonly used in numerous 
processed and confectionary foods or are consumed as animal 
food products. Twenty-one-day exposure to the 3 study diets 
resulted in significant differences in the structure of the enteric 
microbiota as assessed by both Sanger-based and 454-based 
DNA sequencing of 16S rRNA libraries from cecal contents and 
stool, and the findings were evident even within the first week of 
dietary intake. All high-fat diets reduced the richness of the 
microbiota compared with the low-fat diet. Furthermore, the 
low-fat diet promoted Firmicutes but decreased most other 
phyla, whereas polyunsaturated fatty acids and the diet high in 
anhydrous milk fat promoted Bacteroidetes and decreased 
Firmicutes. Interestingly, these changes differed from those 
induced by lard-based, saturated fats,71,72 where Firmicutes pre-
dominate. While diets with milk fat and polyunsaturated fatty 
acids had similar effects on Bacteroidetes and Firmicutes, a sig-
nificant increase in the membership of the Deltaproteobacteria, 
Bilophila wadsworthia, was consistently observed only with the 
milk-fat diet. B wadsworthia has been reported under pathologi-
cal conditions in humans such as appendicitis and other intesti-
nal inflammatory disorders, where it has been shown to be 
genotoxic as well as proinflammatory, in part related to its sul-
fite-reducing properties and production of H2S.73–75 The bloom 
of this rare microorganism without major restructuring of other 
commensal microbiota most likely reflected changes in condi-
tional factors that promote its growth. One potential and major 
source for sulfur is taurine-conjugated (TC) bile acids, which are 
preferentially formed when exposed to milk-fat diets, due to TC 
bile acids’ ability to increase micelle formation and emulsifica-
tion of milk fats.76–78 In this regard, the hepatic conjugation of 
bile acids in mice fed milk-fat diets did indeed shift, to favor the 
formation of taurocholic acid. This effect mostly likely was the 
cause of the B wadsworthia bloom because gavage with TC bile 
acids in mice fed low-fat diets recapitulated the bloom of this 
microorganism. None of the test diets caused the development of 
colitis or other obvious adverse effects in wild-type C57Bl/6 
mice. However, in genetically susceptible interleukin-10-defi-
cient mice of the same background, the rate of spontaneous coli-
tis increased from ~30% to ~70%, with earlier onset of disease. 
Similarly, mice gavaged with TC bile acids on low-fat diets 
exhibited elevated mucosal and mesenteric lymph nodes cyto-
kine levels that, like the milk-fat diet treatment, was associated 
with a TH1 immune response. 
Altogether, these findings support the notion that diets are 
complex and that not all dietary fats have the same effects on 
the enteric microbiota. The emergence of pathobionts such as 
sulfite-reducing bacteria can occur through changes in diet-
induced taurine conjugation of host hepatic bile acids, which, 
through repeated cycles of enterohepatic circulation, increases 
sulfur bioavailability that provides substrate for the growth of 
colonic microbiota capable of sulfur reduction. These types of 
bacteria are often recovered from biopsies and stool of patients 
with IBD79–83 and possibly represent how certain gut microbes 
use bile to their advantage. Bile formation is unique to verte-
brates and omnivores, providing them with the ability to digest 
and use a far greater variety of dietary substrates. Bile also 
provides potent antimicrobial properties that contribute to the 
selection of commensal microorganisms as well as exclusion 
of many potential gut microbiota. In some cases, such as with 
sulfite-reducing bacteria, TC bile acids are used as metabolic 
substrates or for anaerobic respiration, whereas in other cases, 
bile may be essential to suppress symbiotic, commensal micro-
organisms, allowing pathobionts and pathogens opportunity to 
establish a niche in the intestine. In genetically susceptible 
hosts, this development has the capacity to tip a compensated 
state of immune balance to one of chronic inflammation.
Dietary fats differ in their effects on the host microbiota and 
immune system. The findings of our study provide a plausible 
mechanistic basis by which Western-type diets high in satu-
rated fats may increase the prevalence of complex immune-
mediated diseases like IBDs in genetically susceptible hosts. 
Interventional strategies to reshape the gut microbiome in sus-
ceptible individuals should be explored to lower risk and pre-
vent disease.
Use of Fecal Microbial Transplantation to 
Understand and Cure Multiply Recurrent 
Clostridium Difficile Infection (Michael J. 
Sadowsky, Alexander Khoruts, Matthew 
Hamilton, and Alexa Weingarden) 
C difficile infection (CDI) is currently among the most com-
mon antibiotic-related causes of diarrhea in the developed 
world and has rapidly become one of the most commonly 
acquired hospital- and healthcare-acquired infections.84 The 
increase in incidence of this infection during the past decade is 
in large part due to increased use of antibiotics and the global 
emergence of more virulent strains of C difficile. These strains 
are characterized by higher levels of toxin production, sporula-
tion ability, and persistence in the gut.85 These properties have 
contributed to increased incidence and mortality associated 
with CDI. In the U.S. alone, it has been estimated 
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that 20,000–100,000 cases occur each year, but this may be 
underreported.85,86 Moreover, there is an increasing occurrence 
of the multiply recurrent form of CDI (MR-CDI)87,88 leading to 
morbidity and in some cases mortality. While antibiotics have 
been routinely used to treat this disease and can generally sup-
press acute CDI, infection by this bacterium often returns 
within a few weeks of antibiotic stoppage. Interestingly, this 
disease generally follows the rule of doubling. That is, while an 
initial bout of CDI is associated with a 20%−30% chance of 
recurrence, the chance rises by another 20% with each con-
secutive recurrence.89 After 3 or more recurrences, the cycle 
often becomes indefinite, frequently leading to hospitalization. 
Furthermore, it is common for each consecutive recurrence to 
be clinically more severe, leading to multiple hospitalizations, 
morbidity, and loss of productivity. In the U.S. alone, this has 
led to escalating costs of CDI, which have been conservatively 
estimated to be several billion dollars per year.89
The prevalence of MR-CDI can be explained, in large part, 
by the fact that C difficile exists as both a free-living bacterium 
and a spore.90 The vegetative cells of C difficile excrete exotox-
ins that are destructive to colonic epithelium. In addition, 
C difficile resting spore are highly persistent in the intestinal 
tract (and hospital and home environments) and are immune to 
the action of antibiotics. Current hypotheses suggest that the 
normal distal gut microbiota provides colonization resistance 
against C difficile and that antibiotic-induced dysbiosis leads to 
disruption of the microbial community structure of the gut—
leading to colonization by C difficile. Thus, antibiotics are 
themselves one of the major causes of MR-CDI: They suppress 
the vegetative forms of C difficile but also lead to recurrence of 
the infection as they destroy normal gut bacteria and are inef-
fective against spores that germinate once the antibiotic is 
removed (Figure 3).91
Several lines of evidence indicate that patients who receive 
concurrent antibiotics for other indications are at greater risk of 
recurrence.92 Moreover, recent studies have shown that patients 
with MR-CDI have significantly reduced diversity in their 
intestinal bacteria relative to patients having an initial CDI 
infection or a first recurrence.93
Fecal Microbiota Transplantation for CDI
One highly effective solution to this problem is reconstitution 
of normal functioning gut microbial ecology by way of fecal 
microbiota transplantation (FMT).92,94 FMT, previously known 
as fecal bacteriotherapy, is the therapeutic protocol that allows 
for the fastest reconstitution of a normal composition of colon 
microbial communities. We previously showed that FMT 
resulted in prompt and sustained engraftment of donor fecal 
bacteria in a patient with recurrent CDI.95 FMT, administered 
by infusion during a colonoscopy, resulted in completely nor-
malized bowel functioning within 2 days of treatment. Since its 
first proposed use in 1958 by Eiseman et al,96 many hundreds 
of cases have been reported as individual case reports, or small 
case series, with an >90% cumulative success rate in clearing 
recurrent CDI, without any noted adverse events. The history 
and general method used for FMT have been described in sev-
eral recent reviews.97–99
However, despite the long and successful track record, as 
well as great clinical need, the availability of the procedure for 
many patients remains very limited. The lack of wider practice 
of FMT is in great part due to several practical barriers and is 
not due to lack of efficacy. These include lack of reimburse-
ment for donor screening, difficulty in material preparation and 
administration, and aesthetic concerns about conducting the 
procedure. In 2009, we established the FMT program at the 
University of Minnesota that has since overcome many of 
challenges associated with FMT. This has resulted in limited 
use of patient-identified individual donors and greater use of 
rigorously screened “universal” volunteer donors. More impor-
tant, we now use well-prepared standardized frozen fecal 
extracts instead of fresh crudely prepared fecal slurries.
FMT is also very interesting from a basic science perspec-
tive, and this understanding has been aided by use of Illumina-
based high-throughput sequencing of 16S rDNA. Therefore, 
studying the FMT patient population represents an opportunity 
to gain insights into various roles that the distal gut microbiota 
plays in host metabolism and physiology. Our studies have 
shown that patients with MR-CDI have markedly reduced 
microbial species diversity in their distal gut caused by multi-
ple rounds of antibiotics, leading to severe dysbiosis.94,95,100,101 
In these patients, the intestinal tract is dominated by 
Proteobacteria and few or no members of the Bacteroidetes 
and Firmicutes. In contrast, 16S rRNA gene sequence analyses 
showed that FMT, using frozen fecal bacteria from a healthy 
donor, resulted in the stable engraftment of gut microbiota.102 
Post-FMT samples from FMT patients showed an increase in 
the abundance of Firmicutes and Bacteroidetes that repre-
sented ~75%−80% of the total sequence reads.101 It was also 
shown in post-FMT patients that the Proteobacteria and 
Actinobacteria comprised <5% of reads found in patients prior 
to FMT. Members of the Bacteroidetes phylum were most rep-
resented by members of the families Bacteroidaceae, 
Rikenellaceae, and Porphyromonadaceae and were mostly 
comprised of members of the genera Bacteroides, Alistipes, 
and Parabacteroides. Members of the phylum Firmicutes were 
represented by members of the families Ruminococcaceae, 
Lachnospiraceae, Verrucomicrobiaceae, and unclassified 
Clostridiales and members of the Firmicutes.
Taken together, our results demonstrate that frozen, stan-
dardized, fecal microbiota from healthy donors can be used to 
effectively treat recurrent CDI. This procedure restores the 
structure of gut microbiota and clears C difficile in the vast 
majority (>90%) of patients.
How Critical Illness Shifts and Reshapes 
the Microbiome Into a Pathobiome (John 
Alverdy)
No greater stress is imposed on the intestinal microbiome than 
that which develops during human critical illness. Although 
the human microbiome is composed of microorganisms that 
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have coevolved with their hosts and share similar life histories 
of famine, pestilence, plagues, and exposure to xenobiotics, 
there is little evolutionary precedent for the seismic environ-
mental shift that occurs following a major injury (trauma, 
burns, and organ transplantation) and its treatment. Under such 
conditions, the human gut is exposed to alterations in nutrient 
availability (PN), oxygen deprivation (hypoxia, hypotension, 
pressors) or oxygen excess, exposure to agents that affect 
motility (opioids), and multiple antibiotics that erode or 
eliminate the core microbiome. Evidence is now accumulating 
that this degree of stress, in concert with loss of the core micro-
biome, has a major impact on the incidence, course, and out-
come of critical illness.103 Although recovery from critical 
illness is often framed as a function of immune capacity, new 
evidence suggests that the intestinal microbiome itself is a 
potent booster of systemic immune function and, thus, its ero-
sion can adversely affect recovery.104 A new concept in critical 
care management could consider that the extent to which we 
Figure 3. Concept of an abnormal microbial population during an episode of C difficile, and an approach for the treatment of this with 
fecal transplantation. CDI = C difficile infection; FMT = fecal microbiota transplantation. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Gastroenterology & Hepatology,91 copyright 2011. (http://www.nature.com/nrgastro/index.html)
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can understand and maintain core functions of the intestinal 
microbiome during critical illness may itself be immune-
enhancing. Given the degree of diversity and metabolic func-
tion that is present in the normal core microbiome, it is likely 
naïve to think that a few strains of Lactobacilli can fully sup-
plant the degree of functionality required of the intestinal 
microbiome to bolster systemic immune function during criti-
cal illness. Approaches to maintain the core microbiome dur-
ing critical illness need to consider the fact that use of systemic 
antibiotics during critical illness is virtually unavoidable, as 
infections in soft tissues and organs (lung, kidney, wounds) 
will always mandate the use of these agents. A strategy of core 
microbiome maintenance therapy will be necessary even 
before we have a full understanding of all the components of 
the intestinal microbiome that preserve systemic immune func-
tion. This will clearly involve a better understanding of how 
nutrition support during critical illness affects the core micro-
biome and its downstream effect on immunity and 
inflammation.
Conclusions
The promise of personalized medicine is becoming a reality 
as we witness the rapid reduction in cost and time to sequence 
whole genomes and measure whole proteomes and metabo-
lomes. Harnessing and displaying the power inside these 
high-throughput megadatasets are becoming realities as com-
putational scientists, mathematicians, physicists, and bioinfor-
matics experts come together to tackle the data. Yet several 
limitations still exist. As different locations within the gut con-
tain unique microbial communities and there seems to be evi-
dence of “niche specialization,” there must be a uniform 
approach to account for the sample source and the >200 m2 of 
gastrointestinal surface area. We must be cautious not to make 
inferences with data that are purely descriptive, so as to avoid 
the pitfall of overinterpretation of correlative pattern recogni-
tion in lieu of causative mechanisms of disease. We must also 
recognize that an expelled fecal sample may not be an average 
representation of the entire spatial biogeography of the gut. 
Therefore, we should be careful not to display these data and 
make inferences that lack clinical context, as we witnessed 
in the early period of DNA microarrays. Rather the hope is 
that we will witness microbiome-related readouts that 
correlate with disease states and inform the system’s biology. 
Practitioners and patients will then realize the immense power 
of controlling the intake and quality of their food and the 
importance of nourishing their microbial partners to foster 
mutualism and molecular détente within the complex and 
diverse host-microbial interactome.
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